dsm-firmenich Switzerland

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, dsm-firmenich Switzerland sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 13 completed early-phase tilt top decile by trial count

dsm-firmenich Switzerland: 13 sponsored US clinical trials, none currently recruiting.

dsm-firmenich Switzerland sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Absorption; Chemicals, with 1 trials.

Top-decile sponsor footprint

dsm-firmenich Switzerland ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

13 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

COMPLETED Phase 3

Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial

NCT05277376
COMPLETED Phase 2

Photoallergic Potential of 6% Bemotrizinol

NCT05254912
COMPLETED Phase 2

Phototoxicity Potential of 6% Bemotrizinol

NCT05254925
COMPLETED Phase 2

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
COMPLETED Phase 1

Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study

NCT04355286
COMPLETED

Cross-sectional Survey of Omega-3 Fatty Acid Blood Levels

NCT02883764
COMPLETED NA

Growth of Healthy Term Infants Fed Formula Containing DHA-B

NCT02144402
COMPLETED NA

Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia

NCT01737099
COMPLETED

Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device

NCT02052544
COMPLETED Phase 1

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women

NCT01143194
COMPLETED NA

Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health

NCT00698984
COMPLETED Phase 3

Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age

NCT00351624
COMPLETED NA

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

NCT00278135

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Absorption; Chemicals 1
Sunburn 1
Sunscreening Agents 1
Healthy 1

How the dsm-firmenich Switzerland early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 13 completed (100%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Absorption; Chemicals (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

dsm-firmenich Switzerland: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

dsm-firmenich Switzerland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share dsm-firmenich SwitzerlandAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
dsm-firmenich Switzerland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

dsm-firmenich Switzerland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this dsm-firmenich Switzerland page

13 registered trials is a research-attention snapshot, not an endorsement of dsm-firmenich Switzerland or any single study.

  • None of dsm-firmenich Switzerland's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Absorption; Chemicals is the condition dsm-firmenich Switzerland studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Absorption; Chemicals trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

dsm-firmenich Switzerland pipeline card: 13 registered trials from official public datasets.Report a data error.